Monoclonal Antibodies an Option for Oncohematology Patients

Monoclonal antibodies are the best option against SARS-CoV-2 for oncohematology patients, although viral variants may reduce the efficacy of these treatments.

Related Keywords

United States ,United Kingdom ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Madrid ,Spanish ,American ,Karmele Arribalzaga ,Spanish Ministry Of Health ,National Institutes Of Health ,International Society On Thrombosis ,Hemostasis Unit Of The Navarra University Clinic ,American Society Of Hematology ,European Medicines Agency ,Foundation University Hospital ,University Clinical Hospital Of Valladolid ,Association For The Advancement Of Blood Biotherapies ,University Clinical Hospital ,Princesa De La Hospital ,National Institutes ,Spanish Ministry ,Infectious Diseases Department ,Hospital Clinic ,Hemostasis Unit ,Navarra University Clinic ,New England Journal ,International Society ,American Society ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Ituximab ,Thromboembolism ,Hospitals ,Prophylaxis ,Thrombosis ,Deep Venous Thrombosis Dvt ,Deep Vein Thrombosis ,Vt Deep Venous Thrombosis ,Pneumonia ,Cv ,Ardiovascular ,Antiviral ,Amc ,